Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy

Laboratory Investigation

Volumn 87, Issue 5, 2007, Pages 440-455

  Li, Longhu ^a,b   Takemura, Genzou ^a   Li, Yiwen ^a   Miyata, Shusaku ^a   Esaki, Masayasu ^a   Okada, Hideshi ^a   Kanamori, Hiromitsu ^a   Ogino, Atsushi ^a   Maruyama, Rumi ^a   Nakagawa, Munehiro ^a   Minatoguchi, Shinya ^a   Fujiwara, Takako ^c   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c KYOTO WOMEN'S UNIVERSITY   (Japan)

Author keywords

Cardiomyopathy; Cytokines; Doxorubicin; ERK; G CSF; Heart failure

Indexed keywords

CELL PROTEIN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; DESMIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN HEAVY CHAIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR GATA 4; TROPONIN I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CARDIOMYOPATHY; CELL DEGENERATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME INACTIVATION; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; INFLAMMATORY CELL; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SARCOMERE; SINGLE DRUG DOSE; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34247349564     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700530     Document Type: Article

References (43)

1. Olson RD, Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076-3086.
2. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905.
3. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
4. Simpson C, Herr H, Courville KA. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin J Oncol Nurs 2004;8:497-501.
5. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 1998;125(Suppl 10):66-71.
6. Li L, Takemura G, Li Y, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113:535-543.
7. Li K, Sung RY, Huang WZ, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211-2220.
8. Hou XW, Son J, Wang Y, et al. Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.
9. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-2808.
10. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996;88:761-777.
11. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001;98:10344-10349.
12. Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004;109:2572-2580.
13. Ohtsuka M, Takano H, Zou Y, et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J 2004;18:851-853.
14. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005;11:305-311.
15. Cuenda A, Alessi DR. Use of kinase inhibitors to dissect signaling pathways. Methods Mol Biol 2000;99:161-175.
16. LaPointe MC, Mendez M, Leung A, et al. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 2004;286:H1416-H1424.
17. Okabe M, Ikawa M, Kominami K, et al. Green mice as a source of ubiquitous green cells. FEBS Lett 1997;407:313-319.
18. Kushida T, Inaba M, Hisha H, et al. Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood 2001;97:3292-3299.
19. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
20. Aoyama T, Takemura G, Maruyama R, et al. Molecular mechanisms of non-apoptosis by Fas stimulation alone vs apoptosis with an additional actinomycin D in cultured cardiomyocytes. Cardiovasc Res 2002;55:787-798.
21. Li Y, Takemura G, Okada H, et al. Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. Lab Invest 2006;86:32-44.
22. Kim Y, Ma A, Kitta K, et al. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 2003;63:368-377.
23. Aries A, Paradis P, Lefebvre C, et al. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 2004;101:6975-6980.
24. Kawada T, Nakazawa M, Nakauchi S, et al. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci USA 2002;99:901-906.
25. Rosenoff SH, Olson HM, Young DM, et al. Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity. J Natl Cancer Inst 1975;55:191-194.
26. Molkentin JD, Kalvakolanu DV, Markham BE. Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene. Mol Cell Biol 1994;14:4947-4957.
27. Murphy AM, Thompson WR, Peng LF, et al. Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4. Biochem J 1997;322:393-401.
28. Rausch O, Marshall CJ. Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. J Biol Chem 1999;274:4096-4105.
29. Hermans MH, Geijn GJ, Antonissen C, et al. Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells. Blood 2003;101:2584-2590.
30. Lou H, Danelisen I, Singal PK. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;288:H1925-H1930.
31. Tenhunen O, Sarman B, Kerkela R, et al. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J Biol Chem 2004;279:24852-24860.
32. Østergaard C, Benfield T, Gesser B, et al. Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun 1999;67:3430-3436.
33. Boneberg EM, Hartung T. Molecular aspects of anti-inflammatory action of G-CSF. Inflamm Res 2002;51:119-128.
34. Wong SC, Fukuchi M, Melnyk P, et al. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 1998;98:100-103.
35. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-1381.
36. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984-991.
37. Lou H, Danelisen I, Singal PK. Cytokines are not upregulated in adriamycin-induced cardiomyopathy and heart failure. J Mol Cell Cardiol 2004;36:683-690.
38. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999;274:5038-5046.
39. Delgado III RM, Nawar MA, Zewail AM, et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 2004;109:1428-1433.
40. 2 as a potential culprit of anthracycline cardiotoxicity. Cancer Res 2003;63:5992-5998.
41. Kalyanaraman B, Joseph J, Kalivendi S, et al. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 2002;234-235:119- 124.
42. Zhang J, Clark Jr JR, Herman EH, et al. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol 1996;28:1931-1943.
43. Mendez-Ferrer S, Ellison GM, Torella D, et al. Resident progenitors and bone marrow stem cells in myocardial renewal and repair. Nat Clin Pract Cardiovasc Med 2006;3(Suppl 1):S83-S89.